← boardnext 2027-03-14next 2027-05-30next 2028-08
ZLAB
Zai Lab (Shanghai) Co., Ltd.distress 2/10 · well-funded / low risk$20.22-1%today-50% from 52w high
Lead: Solid Tumors
Revenue
$100M
Liquidity
$664M
Runway
6.6 yrs
Shares 1y
+75%
Price & events
+10.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-2.6%
1W
+9.4%
1M
-7.6%
3M
+10.3%
6M
-45.9%
1Y
+4.3%
2Y
-86.5%
5Y
-84.4%
All
Overview
- Market Cap
- $1.79B
- Volume
- 27.98K
- 52 Week Range
- $16.30 – $40.51
- Total Shares
- 88.59M
- Float Shares
- 91.71M
- Short %
- 7.37%
- % Held by Insiders
- 2.16%
- % Held by Institutions
- 31.25%
- RVOL
- 0.03x
- Beta
- 0.76
Pipeline stages · 3 programs
ZL-1109 (VRDN-003)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ZL-1310, Investigator's Choice of Therapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ZL-6201
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03-14 Estimated 50% readout ~2027-05-28 | Phase 3 | ZL-1109 (VRDN-003) | Thyroid Eye Disease (TED) | — | recruiting |
| 2027-05-30 Estimated 50% readout ~2027-06-29 | Phase 1 | ZL-1310, Atezolizumab, Carboplatin | SCLC | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 1/2 | ZL-1310 | Solid Tumors | — | recruiting |
| 2028-06-30 Estimated 50% readout ~2028-09-13 | Phase 3 | ZL-1310, Investigator's Choice of Therapy | Small-cell Lung Cancer | — | recruiting |
| 2028-08 Estimated 50% readout ~2028-08-31 | Phase 1 | ZL-6201 | Solid Tumors, Sarcomas | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $33 (+65% upside) · 12 analysts
- 2026-05-08CitigroupBuy
- 2026-03-18JP MorganOverweight
- 2026-02-27Cantor FitzgeraldOverweight
- 2026-02-05JP MorganOverweight
- 2026-01-07UBSBuy
- 2025-08-11CitigroupBuy
Competitors — Solid Tumors
Recent news
- 2026-07-06Director adds Zai Lab (ZLAB) ADS under pre-set Rule 10b5-1 plan - Stock Titan
- 2026-06-30ZLAB (NASDAQ: ZLAB) insider resale planned on 06/29/2026; recent ADS sales reported - Stock Titan
- 2026-06-29Zai Lab (ZLAB) legal chief settles RSUs, sells ADSs for taxes - Stock Titan
- 2026-06-22Zai Lab (ZLAB) director granted 22,371 restricted ADS vesting in 2027 - Stock Titan
- 2026-06-08(tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 2026-06-08(tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 2026-06-06Zai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed? - Yahoo Finance
- 2026-06-05Zai Lab (ZLAB) Announces Senior Leadership Changes - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.